Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

BlackRock Science & Technology Term Trust Proxy Solicitation & Information Statement 2024

May 21, 2024

31902_psi_2024-05-21_3ab95b2c-ca4e-45af-92ef-013d5ba6bf54.zip

Proxy Solicitation & Information Statement

Open in viewer

Opens in your device viewer

DFAN14A 1 p24-1898dfan14a.htm BLACKROCK SCIENCE AND TECHNOLOGY TERM TRUST

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a)

of the Securities Exchange Act of 1934

Filed by the Registrant o

Filed by a Party other than the Registrant þ

Check the appropriate box:

o Preliminary Proxy Statement
o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
o Definitive Proxy Statement
þ Definitive Additional Materials
o Soliciting Material Under Rule 14a-12

BlackRock Science and Technology Term Trust

(Name of Registrant as Specified In Its Charter)

Saba Capital Management, L.P.

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Field: Page; Sequence: 1

Field: /Page

Payment of Filing Fee (Check all boxes that apply):

þ No fee required.
o Fee paid previously with preliminary materials.
o Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

Field: Page; Sequence: 2

Field: /Page

Boaz R. Weinstein posted the below message to his X account.

Field: Page; Sequence: 3

Field: /Page

Saba Capital Management, L.P. sent the below message to shareholders.

Field: Page; Sequence: 4

Field: /Page

Field: Page; Sequence: 5

Field: /Page

Boaz Weinstein provided the following written statements to members of the media.

"[ICI] is a lobbying group and a surrogate frequently deployed by BlackRock and other managers when they cannot defend unacceptable performance."

"The blame for a lack of closed-end fund issuance sits squarely with managers – not investors – considering the steep discounts and poor governance that persists under their watch."

"Saba's actions have proven to be helpful, not harmful, for long-term shareholders of the closed-end funds we invest in. The secret is our medicine always works – shareholders all gain when offered a significant narrowing or total elimination of discounts to net asset value."